Keywords: Microsatellite instability; Nivolumab; PD-L1; Pembrolizumab; TILs;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Immunological; Dysfunction; Sepsis; Antigen presentation; T/B lymphocytes; Tregs; PD-1; Immunoglobulins; Neutrophils; Complement; CNC; circulating neutrophil count; G-CSF; granulocyte-colony stimulating factor; GM-CSF; granulocyte-macrophage colony stimul
Keywords: Ab; Antibody; ABC; ATP-binding cassette; AIOM; Associazione Italiana di Oncologia Medica; ALCAM; Activated leukocyte cell adhesion molecule; APOD; Apolipoprotein D; AR; androgen receptor; AURKA; Aurora kinase A; AURKB; Aurora kinase B; BCS; Biopharmaceuti
Keywords: Immune check-point inhibitors; PD-1; PD-L1; Immunohistochemistry; Biomarker assay;
Keywords: Cancer treatment; Radiotherapy; Checkpoint; Immunotherapy; CTLA-4; PD-L1;
Keywords: EGFR mutation; EGFR-TKI therapy; Immunohistochemistry; Lung adenocarcinoma; PD-L1
Keywords: Gy; gray; Ab; antibody; TGF-β; transforming growth factor-β; TNF; tumor necrosis factor; SASP; senescence-associated secretory phenotype; MCP-1; monocyte chemoattractant protein-1; MHC; major histocompatibility complex; DAMP; damage-associated molecular
Keywords: RA; rheumatoid arthritis; DCs; dendritic cells; TolDCs; tolerogenic dendritic cells; NSAIDs; non-steroidal anti-inflammatory drugs; GC; glucocorticoids; DMARDs; disease-modifying anti-rheumatic drugs; TLRs; toll-like receptors; CLRs; cell surface C-type l
Keywords: Immunotherapy; NSCLC; Immune checkpoint blockade; CTLA-4; PD-1; PD-L1
Keywords: AA; abiraterone acetate; ADT; androgen deprivation therapy; AR; androgen receptor; AR-V; AR splice variant; CRPC; castration-resistant prostate cancer; CTC; circulating tumor cell; CYP; cytochrome P450; FDA; Food and Drug Administration; LBD; ligand-bindi
Keywords: Antibodies; Immunoconjugates; Immunotoxins; Ab; antibody; Ag; antigen; ADCC; antibody-dependent cell mediated cytotoxicity; ALL; acute lymphoblastic leukemia; AML; acute myeloid leukemia; AKT; protein kinase B; APC; antigen-presenting cell; Apo2L/TRAIL; t
Keywords: 17-AAG; 17-(Allylamino)-17-demethoxygeldanamycin; 17-DMAG; 17-Dimethylaminoethylamino-17-demethoxygeldanamycin; AKT; v-akt murine thymoma viral oncogene homolog; APC; antigen presenting cell; ATM; Ataxia telangiectasia mutated; ATR; Ataxia telangiectasia
Keywords: Radiation; Immunotherapy; Dose; Fractionation; MHC-I; major histocompatibility class I; ICAM-1; intercellular adhesion molecules-1; CEA; carcinoembryonic antigen; CTL; cytotoxic T cells; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; gp 100; glycopr
Keywords: Ag; antigen; APC; antigen presenting cell; AQP4; aquaporin 4; BDNF; brain-derived neurotrophic factor; CD; cluster of differentiation; CCL; C-C ligand; chABC; chondroitinase ABC; CNS; central nervous system; COX; cyclooxygenase; CTLA-4; cytotoxic T lymp
Keywords: 5-ALA; 5-aminolevulinic acid; 5-FU; 5-fluorouracil; APC; antigen presenting cell; BCC; basal cell carcinoma; CAP; cold atmospheric plasma; CM; cutaneous malignant melanoma; CNP; cerium oxide nanoparticle; CNT; carbon nanotube; COX-2; cyclooxygenase II; CP
Keywords: Breast cancer; HER-2-negative; Resistance; Biologic targeted agent; Combination therapy; ABC; advanced breast cancer; AE; adverse event; AI; aromatase inhibitor; AKT; protein kinase; BC; breast cancer; CDK; cyclin-dependent kinase; CT; chemotherapy; CTLA;
Keywords: Breast cancer; Immune system; Biomarkers; Immunotherapies; Immune checkpoint blockade; Tumor vaccines; ADCC; antibody dependent cellular cytotoxicity; BiTES; bispecific single chain monoclonal antibodies; CAR; T cells engineered to express artificial chim
Keywords: AE; adverse effect; APC; antigen-presenting cells; CI; confidence interval; CP; carboplatin and paclitaxel; CR; complete response; CTLA-4; cytotoxic T-lymphocyte-associated antigen-4; cuSCC; cutaneous squamous cell carcinoma; FDA; Food and Drug Administ
Keywords: APC(s); antigen presentation cell(s); ARG1; arginase-1; Breg(s); regulatory B (cells); CAF(s); cancer-associated fibroblast(s); CD; cluster of differentiation protein; CD40L; cluster of differentiation protein 40 ligand; C/EBP; CAAT/enhancer binding prote
Keywords: Immunotherapy; Non-small cell lung cancer; PD-L1; CTLA-4; Ipilimumab; Nivolumab;
Keywords: Human colorectal cancer; PD-L1; Prognostic factors; Overall survival; Tissue microarrays;
Keywords: DC; dendritic cell; TAA; tumour associated antigen; NC; nucleocapsid; MA; matrix; CA; capsid; RRE; rev response element; cppt; central DNA flap; WPRE; woodchuck post-transcriptional response element; TCR; T cell receptor; pMHC; peptide-MHC complex; Th;
Keywords: Bladder cancer; Checkpoint inhibitors; 5H1; PD-1; PD-L1
ERα is a negative regulator of PD-L1 gene transcription in breast cancer
Keywords: Breast cancer; PD-L1; ERα;
Nivolumab-induced alopecia areata: A reversible factor of good prognosis?
Keywords: alopecia areata; anti-programmed cell death protein-1; drug adverse event; immune related; lung cancer; melanoma; nivolumab; AA; alopecia areata; CTLA-4; cytotoxic T-lymphocyte-associated antigen-4; ICI; immune checkpoint inhibitors; PD-1; programmed
Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 predicts poor prognosis in hepatocellular carcinoma
Keywords: Liver cancer; LGR5; Immunohistochemistry; Clinicopathology; Overall survival; HBs; hepatitis B virus; EMT; epithelial-to-mesenchymal transition; Flot2; flotillin-2; GPCR; G-protein-coupled receptor; GPR49; G-protein coupled receptor 49; GRP78; glucose-reg
Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy
Keywords: Clear cell renal cell carcinoma; Immune checkpoint; PD-L1; Immunohistochemistry; Intratumor heterogeneity; Multisite tumor sampling; Targeted therapy;
Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types
Keywords: PD-L1; Circulating tumor DNA; Liquid biopsy; Cancer;
PD-L1 expression according to the EGFR status in primary lung adenocarcinoma
Keywords: PD-L1; EGFR; Lung adenocarcinoma;
Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4
Keywords: PD-L1; Programmed cell death-ligand 1; PD-1; programmed cell death-1; CBIS; cell-based immunization and screening; SCC; squamous cell carcinoma; ACC; adenoid cystic carcinoma; MEC; mucoepidermoid carcinoma; CTLA-4; cytotoxic T-lymphocyte-associated antige
Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients
Keywords: KRAS; PD-L1; Immune microenvironment; Lung adenocarcinoma;
HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers
Keywords: Human immunodeficiency virus; Human Papillomavirus; Head and neck cancer; PD-1; PD-L1; Immune checkpoint blockade; Antigen processing machinery;
Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1
Keywords: Diffuse large B-cell lymphoma; Immune response; miR-195; PD-L1;
Programmed death ligand 1 expression and CD8+ tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer
Keywords: Non-small cell lung cancer; Brain metastases; PD-L1; CD8+ tumor-infiltrating lymphocyte; Heterogeneity;
Synergistic tumoricidal effect of combined hPD-L1 vaccine and HER2 gene vaccine
Keywords: PD-L1; HER2; Vaccine; Immune evasion; CD4+ Foxp3+ regulatory T cells;
Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications
Keywords: BRCA1-associated protein1; BAP1; mesothelin; PD-L1; mesothelioma; overall survival;
Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma
Keywords: Malignant pleural mesothelioma; Microsatellite instability; Mismatch repair protein; Immunohistochemistry; PD-L1;
Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma
Keywords: Early stage lung adenocarcinoma; Mass-spectrometry sequencing; Mutation profiling; PD-L1; Tissue micro-array;
PD-L1 expression in large cell neuroendocrine carcinoma of the lung
Keywords: Lung cancer; Neuroendocrine carcinoma; LCNEC; PD-L1; PD-1;
MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells
Keywords: CTL; cytotoxic T lymphocytes; EGFR; epidermal growth factor receptor; FACS; fluorescence-activated cell sorting; HCC; hepatocellular carcinomas; Inr; initiator; PD-1; programmed cell death protein-1; PD-L1; programmed cell death-ligand; T-ALL; T cell acut
Expression of B7-H2 on CD8+ T cells in colorectal cancer microenvironment and its clinical significance
Keywords: MHC; major histocompatibility complex; TCR; T cell receptor; CTLA-4; cytotoxic T lymphocyte associated antigen-4; PD-1; programmed deth-1; PD-L1; programmed deth-1 ligand; TILs; tumor infiltrating lymphocytes; SPF; specific pathogen free; B7-H2; T cells;
Rescue of iCIKs transfer from PD-1/PD-L1 immune inhibition in patients with resectable tongue squamous cell carcinoma (TSCC)
Keywords: OSCC; Oral squamous cell carcinoma; TSCC; Tongue squamous cell carcinoma; HNSCC; Head and neck squamous cell carcinoma; iCIKs; Improving cytokine-induced killer cells; TILs; Tumour-infiltrating lymphocytes; PBMCs; Peripheral blood mononuclear cells; IRB;
Bone marrow derived M2 macrophages protected against lipopolysaccharide-induced acute lung injury through inhibiting oxidative stress and inflammation by modulating neutrophils and T lymphocytes responses
Keywords: Acute lung injury; Bone marrow derived M2 macrophage; Neutrophil; Regulatory T lymphocyte; PD-L1;
Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma
Keywords: Thymoma; Thymic carcinoma; PD-L1; IDO; FOXP3;
PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
Keywords: PD-L1; Lung; Cancer; Heterogeneity; Biopsies;
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting
Keywords: CI; confidence interval; DCR; disease control rate; DOC; docetaxel; EMA; European Medicines Agency; FDA; US Food and Drug Administration; HR; hazard ratio; ITT; intent to treat; NSCLC; non-small cell lung cancer; OR; odds ratio; ORR; objective response ra
Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis
Keywords: Expression; Meta-analysis; Non small cell lung cancer; PD-L1;
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Keywords: Pembrolizumab; Melanoma; PD-1; PD-L1;
PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations
Keywords: PD-1; PD-L1; CTLA-4; DNA methylation; Lower-grade glioma; Prognosis;
Combining chemotherapy with PD-1 blockade in NSCLC
Keywords: NSCLC; non-small cell lung cancer; PT-DC; platinum-doublet chemotherapy; ORR; objective response rate; PD-1; programmed cell death-1; PD-L1; programmed death ligand-1; CTLA-4; cytotoxic T-lymphocyte antigen-4; DC; dendritic cell; TME; tumor microenvironme